



Model List of Essential Medicines



Medicines for COVID-19 [General information](#)

Section

Medicines for COVID-19

- Refer to WHO living guidelines

Indications

[COVID-19](#)



Abacavir [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + dolutegravir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + lamivudine + lopinavir + ritonavir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

[unspecified](#)



Aciclovir [General information](#)

Section

Antitherpes medicines

- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Indications

[Herpes simplex infections Zoster Varicella](#)



Albendazole [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

[Trichuriasis Echinococcosis Cysticercosis Enterobiasis Hookworm diseases Ascariasis](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)

Indications

[Other specified echinococcosis Cysticercosis of central nervous system](#)

Section

Antifilarials

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

[Lymphatic filariasis](#)



Amikacin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

[Neutropenia \(high-risk\)](#) co-prescribed with [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescribed with [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [ceftriaxone Acute pyelonephritis \(severe\)](#)

Second choice

co-prescribed with [cloxacillin Sepsis without septic shock](#)

Section

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Amodiaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)



Amodiaquine - sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package

Indications

[Malaria](#)



Amoxicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

First choice

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(uncomplicated\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)



Amoxicillin + clavulanic acid [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Infectious cystitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Peritonitis \(mild-moderate\)](#) [Acute sinusitis](#) [Peritoneal abscess \(mild-moderate\)](#) [Chronic obstructive pulmonary disease with acute exacerbation](#)

Second choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Osteomyelitis or osteitis](#) [Acute otitis media](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Amphotericin B [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

[Candidosis](#) [Blastomycosis](#) [Cryptococcosis](#) [Coccidioidomycosis](#) [Histoplasmosis](#) [Sporotrichosis](#) [Aspergillosis](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

[Visceral leishmaniasis](#)



Ampicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Anidulafungin [General information](#)

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for [Systemic or invasive candidosis](#)



Ansuvimab [General information](#)

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 400 mg powder for injection

Indications

[Ebola virus disease](#)



Arpraziquantel [General information](#)

Section

Antischistosomes and other antitrematode medicines

- Oral > Solid > dispersible tablet: 150 mg

Indications

Therapeutic equivalent to [praziquantel](#) for [Schistosomiasis](#)



Artemether [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artemether + lumefantrine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 120 mg
- Oral > Solid > tablet: 20 mg + 120 mg

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
- Local > Rectal > Other: 100 mg capsules

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate + amodiaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate + mefloquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate + pyronaridine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)
- Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate - sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Atazanavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage](#)

[unspecified](#)



Atazanavir + ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage](#)

[unspecified](#)



Atoltivimab + maftivimab + odesivimab [General information](#)

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

[Ebola virus disease](#)



Azithromycin [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

[Trachoma](#) [Cholera](#) [Cholera \[children\]](#) [Paratyphoid fever](#) [Chlamydia trachomatis](#) [Typhoid fever](#) [Yaws](#) co-prescribed with [ceftriaxone](#) [Gonococcal infection](#)

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescribed with [cefixime](#) [Gonococcal infection](#)



Aztreonam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified bacterial diseases](#)



Bedaquiline [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Benzathine benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection

Indications

First choice

[Congenital syphilis \[children\]](#) [Syphilis](#)

Other indications

[Bacterial infection of unspecified site](#)

Benznidazole [General information](#)

Section

American trypanosomiasis

- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

Indications

[Chagas disease](#)

Benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Congenital syphilis \[children\]](#) [Syphilis](#)
[Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#)
[Sepsis without septic shock](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Capreomycin [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Caspofungin [General information](#)

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for [Systemic or invasive candidosis](#)

Cefalexin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

First choice

[Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

[Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Cefazolin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

[Other specified prophylactic measures](#) [Other specified prophylactic measures](#)

Second choice

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Surgical site infection](#)

Cefepime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)

Cefiderocol [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Cefixime [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)

Cefotaxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Sepsis without septic shock](#) [Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Ceftaroline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

[Other specified bacterial diseases](#)

Ceftazidime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

Ceftriaxone [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Inflammatory and other diseases of prostate \(severe\) Bacterial meningitis Acute pyelonephritis \(severe\) Other specified pneumonia \(Hospital-acquired pneumonia\) Paratyphoid fever Typhoid fever Peritonitis \(mild-moderate\) Peritonitis \(severe\) Peritoneal abscess \(mild-moderate\) Peritoneal abscess \(severe\) Gonococcal infection Endophthalmitis Bacterial pneumonia \(Community-acquired pneumonia - severe\) Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\] co-prescribed with metronidazole Necrotising fasciitis](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Bacterial infection of joint](#) [Sepsis without septic shock](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Cefuroxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Other specified prophylactic measures](#)

Chloramphenicol [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Chloroquine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium ovale](#) [Malaria due to Plasmodium malariae](#) [Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

[Malaria due to Plasmodium vivax](#)

Ciprofloxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

Second choice

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)



Clarithromycin [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescribed with [ceftriaxone](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choice

[Acute pharyngitis](#) co-prescribed with [amoxicillin + clavulanic acid](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)



Clindamycin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

[Necrotising fasciitis](#)

Second choice

[Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Clofazimine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Section

Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Leprosy](#)



Clotrimazole [General information](#)

Section

Antifungal medicines

- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

[Vulvovaginal candidosis](#)



Cloxacillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

[Sepsis without septic shock](#)

Other indications

[Bacterial infection of unspecified site](#)



Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Colistin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)



Cycloserine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Daclatasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

[Chronic hepatitis C](#)

Daclatasvir + sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

[Chronic hepatitis C](#)

Dapsone [General information](#)

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

[Leprosy](#)

Daptomycin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Darunavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Dasabuvir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 250 mg tablet

Indications

[Chronic hepatitis C](#)

Delafloxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Delamanid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Dicloxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Didanosine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Diethylcarbamazine [General information](#)

Section

Antifilarials

- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

[Lymphatic filariasis](#)

Dihydroartemisinin + piperaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
- Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

Diloxanide [General information](#)

Section

Antiamoebic and anti giardiasis medicines

- Oral > Solid: 500 mg (furoate)

Indications

[Amoebiasis](#)

Dolutegravir [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Dolutegravir + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Doxycycline [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

First choice

[Cholera Chlamydia trachomatis](#)

Second choice

[Cholera \[children\] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

[Malaria due to Plasmodium falciparum](#)



Efavirenz [General information](#)

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Solid: 600 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Efavirenz + emtricitabine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Efavirenz + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [efavirenz + emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Eflornithine [General information](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

[Gambiense trypanosomiasis](#)

Elbasvir + grazoprevir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 100 mg

Indications

[Chronic hepatitis C](#)

Emtricitabine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Emtricitabine + rilpivirine + tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Emtricitabine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)

Emtricitabine + tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Entecavir [General information](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg

Indications

[Chronic hepatitis B](#)

Eravacycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

[Carbapenem resistant Enterobacterales](#)

Erythromycin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Ethambutol [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Other specified tuberculosis Tuberculosis](#)

Ethambutol + isoniazid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)



Ethambutol + isoniazid + pyrazinamide + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)



Ethambutol + isoniazid + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

[Tuberculosis](#)



Ethionamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

[Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis](#)



Fexinidazole [General information](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

[Rhodesiense trypanosomiasis Gambiense trypanosomiasis](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

[Rhodesiense trypanosomiasis Gambiense trypanosomiasis](#)



Fifth generation cephalosporins [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)



Flomoxef [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)



Flucloxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Fluconazole [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg

Indications

[Cryptococcosis](#) [Candidosis](#)

Flucytosine [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule

Indications

[Cryptococcosis](#)

Fosfomycin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Fourth generation cephalosporins [General information](#)

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Gatifloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Gentamicin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

[Neonatal meningitis](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) co-prescribed with [amoxicillin](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [ampicillin](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [ampicillin](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [ampicillin](#) [Peritonitis \(severe\)](#) co-

prescribed with [ampicillin Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ampicillin Peritoneal abscess \(severe\)](#) co-prescribed with [ampicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [benzylpenicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [benzylpenicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

Second choice

[Gonococcal infection Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)

Glecaprevir + pibrentasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

[Chronic hepatitis C](#)

Griseofulvin [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg

Indications

[Dermatophytosis](#)

Hydroxychloroquine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

Indications

Therapeutic equivalent to [chloroquine](#) for [Malaria due to Plasmodium falciparum](#)

Imipenem + cilastatin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Neutropenia \(high-risk\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Imipenem + cilastatin + relebactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Carbapenem resistant Enterobacterales Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa](#)

Indinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 400 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Isoniazid [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

[Other specified tuberculosis Tuberculosis](#)

Isoniazid + pyrazinamide + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

[Tuberculosis](#)

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim [General information](#)

Section

Medicines for prevention of HIV-related opportunistic infections

- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

[Other specified prophylactic measures](#)

Isoniazid + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

[Tuberculosis](#)

Isoniazid + rifapentine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

[Latent tuberculosis](#)

Itraconazole [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg

Indications

[Chronic pulmonary aspergillosis Chromoblastomycosis Histoplasmosis Talaromycosis Sporotrichosis Paracoccidioidomycosis](#)

Ivermectin [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 3 mg

Indications

[Strongyloidiasis Ascariasis Trichuriasis Ancylostomiasis Hookworm diseases](#)

Section

Medicines for ectoparasitic infections

- Oral > Solid > tablet: 3 mg

Indications

[Scabies](#)

Section

Antifilarials

- Oral > Solid > tablet: 3 mg

Indications

[Lymphatic filariasis Onchocerciasis](#)



Kanamycin (injection) [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Lamivudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lamivudine + nevirapine + zidovudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Contact with or exposure to human immunodeficiency virus](#)



Lamivudine + zidovudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Ledipasvir + sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 90 mg + 400 mg tablet

Indications

[Chronic hepatitis C](#)



Levamisole [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

[Ascariasis](#)



Levofloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Linezolid [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Lopinavir + ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Mebendazole [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

[Ascariasis Enterobiasis Trichuriasis Hookworm diseases](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

[Other specified echinococcosis](#)



Mefloquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 250 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 250 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Meglumine antimoniate [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

Indications

[Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis](#)

Melarsoprol [General information](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

[Gambiense trypanosomiasis Rhodesiense trypanosomiasis](#)

Meropenem [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

[Neonatal meningitis Peritonitis \(severe\) Peritoneal abscess \(severe\) Neutropenia \(high-risk\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Meropenem + vaborbactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)

Meticillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Metronidazole [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

First choice

[Intestinal infections due to Clostridioides difficile](#) [Trichomoniasis](#) [Necrotising fasciitis](#) co-prescribed with [cefazolin](#) [Other specified prophylactic measures](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(severe\)](#)

Second choice

co-prescribed with [ciprofloxacin](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ciprofloxacin](#) [Peritonitis \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antiamoebic and anti giardiasis medicines

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

[Amoebiasis](#)



Micafungin [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

[Systemic or invasive candidosis](#)



Miltefosine [General information](#)

Section

Antileishmaniasis medicines

- Oral > Solid: 10 mg; 50 mg

Indications

[Visceral leishmaniasis](#) [Cutaneous leishmaniasis](#) [Mucocutaneous leishmaniasis](#)



Moxidectin [General information](#)

Section

Antifilarials

- Oral > Solid > tablet: 2 mg

Indications

Therapeutic equivalent to [ivermectin](#) for [Lymphatic filariasis](#) Therapeutic equivalent to [ivermectin](#) for [Onchocerciasis](#)



Moxifloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

Indications

[Tuberculosis Multi-drug resistant Mycobacterium tuberculosis](#)

Nafcillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Nalidixic acid [General information](#)

Section

Anti-infective medicines

- Oral > Solid: 250 mg; 500 mg

Indications

[Shigella resistant to unspecified antibiotic](#)

Nelfinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 250 mg (as mesilate)
- Oral > Other: 50 mg per g oral powder

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Nevirapine [General information](#)

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Niclosamide [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid: 500 mg tablet (chewable)

Indications

[Hymenolepiasis](#) [Diphyllobothriasis](#) [Taeniasis due to Taenia saginata](#) [Taeniasis due to Taenia solium](#)

Nifurtimox [General information](#)

Section

American trypanosomiasis

- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

[Chagas disease](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

[Gambiense trypanosomiasis](#)

Nitrofurantoin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

[Infectious cystitis](#)

Nystatin [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 100000 IU per mL
- Local > Topical > Other: 100000 IU pessary
- Oral > Solid > dosage form: 500000 IU
- Oral > Solid > lozenge: 100000 IU

Indications

[Candidosis](#)

Ofloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Omadacycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Ombitasvir + paritaprevir + ritonavir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

[Chronic hepatitis C](#)

Oseltamivir [General information](#)

Section

Other antivirals

- Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

[Influenza due to identified seasonal influenza virus](#)

Oxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Oxamniquine [General information](#)

Section

Antischistosomes and other antitrematode medicines

- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid > capsule: 250 mg

Indications

[Schistosomiasis due to Schistosoma mansoni](#)

Oxazolindinones [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

P-aminosalicylate sodium [General information](#)

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

P-aminosalicylic acid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Paromomycin [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Indications

[Visceral leishmaniasis](#)

Section

Antiamoebic and anti-giardiasis medicines

- Oral > Liquid: 125 mg per 5 mL as sulfate
- Oral > Solid: 250 mg as sulfate

Indications

[Amoebiasis](#)

Pegylated interferon alfa (2a) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)

Pegylated interferon alfa (2b) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Pentamidine [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Indications

[Visceral leishmaniasis](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

Indications

[Gambiense trypanosomiasis](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)

Indications

[Pneumocystosis](#)



Phenoxyethylpenicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\) Periapical abscess without sinus Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Piperacillin + tazobactam [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

[Neutropenia \(high-risk\) Other specified pneumonia \(Hospital-acquired pneumonia\) Peritonitis \(severe\) Peritoneal abscess \(severe\)](#) co-prescribed with [clindamycin Necrotising fasciitis](#)



Plazomicin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)



Polymyxin B (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Polymyxins [General information](#)

Section

Reserve group antibiotics

◦ .

Indications

[Other specified bacterial diseases](#)

Potassium iodide [General information](#)

Section

Antifungal medicines

◦ Local > Topical > Solution: Saturated solution

Indications

[Sporotrichosis](#)

Praziquantel [General information](#)

Section

Cysticidal medicines

◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Cysticercosis of central nervous system](#)

Section

Antischistosomes and other antitrematode medicines

◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Paragonimiasis](#) [Clonorchiasis](#) [Opisthorchiasis](#) [Schistosomiasis](#)

Section

Intestinal anthelmintics

◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Diphyllobothriasis](#) [Taeniasis due to Taenia saginata](#) [Taeniasis due to Taenia solium](#) [Hymenolepiasis](#)

Pretomanid [General information](#)

Section

Antituberculosis medicines

◦ Oral > Solid > tablet: 200 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Primaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

◦ Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)

Indications

[Malaria due to Plasmodium ovale](#) [Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

Procaine benzylpenicillin [General information](#)

Section

Access group antibiotics

◦ Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

[Congenital syphilis \[children\]](#)

Second choice

[Syphilis](#)

Proguanil [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Protionamide [General information](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [ethionamide](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Pyrantel [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

[Ascariasis Enterobiasis Trichuriasis Hookworm diseases](#)

Pyrazinamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

[Tuberculosis](#)

Pyrimethamine [General information](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 25 mg

Indications

[Toxoplasmosis](#)

Quinine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion

Indications

[Malaria due to Plasmodium falciparum](#)

Raltegravir [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Ravidasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

[Chronic hepatitis C](#)



Ribavirin [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

[Chronic hepatitis C](#)

Section

Other antivirals

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

[Viral haemorrhagic fever, not elsewhere classified](#)



Rifabutin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 150 mg

Indications

[Tuberculosis](#)



Rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
- Parenteral > General injections > IV: 600 mg in vial powder for injection

Indications

[Tuberculosis Other specified tuberculosis](#)

Section

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Indications

[Leprosy](#)



Rifapentine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 150 mg

Indications

[Tuberculosis Latent tuberculosis](#)



Ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Saquinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 200 mg; 500 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Simeprevir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

[Chronic hepatitis C](#)

Sodium stibogluconate [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

[Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis](#)

Sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

[Chronic hepatitis C](#)

Sofosbuvir + velpatasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

[Chronic hepatitis C](#)

Spectinomycin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)

Stavudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Streptomycin (injection) [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Sulfadiazine [General information](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 500 mg

Indications

[Toxoplasmosis](#)

Section

Anti-infective medicines

- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

Indications

[Bacterial infection of unspecified site](#)



Sulfadimidine [General information](#)

Section

Anti-infective medicines

- Oral > Liquid: 500 mg per 5 mL
- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

Indications

[Bacterial infection of unspecified site](#)



Sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 500 mg + 25 mg tablet
- Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet

Indications

[Malaria due to Plasmodium falciparum Malaria](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 500 mg + 25 mg tablet

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)



Sulfamethoxazole + trimethoprim [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

First choice

[Infectious cystitis](#)

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10

mL ampoule

- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

[Pneumocystosis](#)



Suramin sodium [General information](#)

Section

Antifilarials

- Parenteral > General injections > IV: 1 g in vial

Indications

[Filariasis](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IV: 1 g in vial

Indications

[Rhodesiense trypanosomiasis](#)



Tedizolid [General information](#)

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Enterococcus](#)



Tenofovir alafenamide [General information](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 25 mg

Indications

[Chronic hepatitis B](#)



Tenofovir disoproxil fumarate [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Chronic hepatitis B](#)



Terizidone [General information](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [cycloserine](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)



Tetracycline [General information](#)

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)



Tigecycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Tinidazole [General information](#)

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to [metronidazole](#) for [Amoebiasis](#)

Triclabendazole [General information](#)

Section

Antischistosomal and other antitrematode medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

[Paragonimiasis](#) [Fascioliasis](#)

Trimethoprim [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

First choice

[Infectious cystitis](#)

Valganciclovir [General information](#)

Section

Other antivirals

- Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
- Oral > Solid > tablet: 450 mg (as hydrochloride)

Indications

[Cytomegaloviral retinitis](#)

Vancomycin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

[Necrotising fasciitis](#) co-prescribed with [ceftazidime](#) [Endophthalmitis](#) co-prescribed with [ceftriaxone](#) [Endophthalmitis](#)

Second choice

[Intestinal infections due to Clostridioides difficile](#) [Neutropenia \(high-risk\)](#)

Other indications

[Methicillin resistant Staphylococcus aureus](#)

Voriconazole [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection
- Oral > Liquid: 40 mg per mL powder for oral liquid
- Oral > Solid: 50 mg tablet; 200 mg tablet

Indications

[Invasive aspergillosis](#) [Chronic pulmonary aspergillosis](#)



Zidovudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)